News | June 21, 2023
DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
It is a two dose vaccine to be administered intramuscularly at 28 days apart
It is being developed by Pune-based Gennova Biopharmaceuticals
The trial will be conducted across eight sites in Maharashtra
The company has to approach the DCGI for approval to commence the trials
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)